Macrophages have critical roles in the pathogenesis of atherosclerosis by activating the innate immune system and producing inflammatory cytokines. Accumulating evidence indicates that angiotensin type 1 receptor (AT1R) blockers exert antiinflammatory effects in inflammatory diseases including atherosclerosis. In this study, we investigated the effect of losartan, an AT1R blocker, on the proinflammatory gene expression induced by bacterial lipopolysaccharide (LPS) in a well-defined in vitro human THP-1 macrophage system. We found that losartan significantly attenuated the LPS-induced expression of proinflammatory genes TNF-a, IL-8 and COX-2. However, exogenous angiotensin II (AngII) had no effect on LPS-induced inflammatory signaling despite the expression of AT1R. In addition, losartan did not block LPS-induced IjB phosphorylation, which is downstream of Toll-like receptor activation. Peroxisome proliferator-activated receptor-gamma (PPARc) antagonists, GW9662 and T0070907, reversed the inhibitory effects of losartan on LPS-induced TNF-a and IL-8 expression in THP-1 macrophages. These observations suggest that losartan inhibits LPS-induced proinflammatory gene expression in macrophages by activating the PPARc pathway rather than by the competitive inhibition of AT1R binding to AngII.
INTRODUCTION
Atherosclerosis comprises a series of highly specific cellular and molecular inflammatory responses. 1 It is widely accepted that enhanced renin-angiotensin system (RAS) signaling contributes to the inflammatory reactions in atherosclerosis. 2, 3 Angiotensin II (AngII) stimulates the expression of inflammatory cytokines and chemokines, which are tightly linked to endothelial cell dysfunction, inflammatory cell infiltration and vascular smooth muscle cell migration. Through its binding to the angiotensin type 1 receptor (AT1R), AngII activates multiple intracellular signaling pathways, including G protein-coupled, mitogen-activated protein kinase, and non-receptor tyrosine kinase pathways. These signaling pathways are involved in AngII-induced cytokine and chemokine expression. 4 Accumulating evidence indicates that the Toll-like receptor (TLR)-signaling pathways also play a crucial role in the initiation and progression of atherosclerosis. [5] [6] [7] In addition, TLRs are expressed in infiltrating macrophages, endothelial cells and vascular smooth muscle cells in advanced atherosclerotic lesions, which might contribute to plaque activation. Different TLRs recognize a variety of molecules, including lipids and nucleic acids. On binding the ligand, TLRs recruit adaptor proteins to the cytoplasmic signaling domain, the Toll/ interleukin-1 (IL-1) receptor domain, resulting in the activation of signaling cascades to produce proinflammatory cytokines and chemokines. 8 It was reported that the proinflammatory effect of AngII in vascular smooth muscle cells involved the TLR4 pathway. 9 In addition, AT1R blockers exerted anti-inflammatory effects to suppress the inflammatory response induced by a TLR4 ligand, lipopolysaccharide (LPS). 10, 11 These lines of evidence suggested that RAS would interact with TLR-signaling pathways during the inflammatory reaction of atherosclerosis. To clarify this point, we investigated the effect of the AT1R blocker losartan on the LPS-induced inflammatory reaction that is linked to the TLR4-signaling pathway in macrophages because the macrophages and the inflammatory cytokines they produce are crucial to the pathogenesis of atherosclerosis. 1 We focused on three proinflammatory genes, TNF-a, IL-8 and COX-2, which are expressed under the control of the LPS-TLR4 pathway. It was found that losartan exerted anti-inflammatory effects on the LPS-induced reactions, but these effects seemed to be independent from the antagonistic function to AT1R. We report here that losartan inhibits LPS-induced inflammatory signals through a peroxisome proliferatoractivated receptor-gamma (PPARg)-dependent process in a human monocyte/macrophage cell line, THP-1.
METHODS

Cell culture
The human THP-1 cell line (American Type Culture Collection, Manassas, VA, USA) was cultured in RPMI-1640 (Sigma, St Louis, MO, USA) medium containing 10% fetal calf serum (FCS) (Nichirei, Tokyo, Japan) and 1% penicillin/streptomycin (P/S) (Gibco, Grand Island, NY, USA) at 37 1C in a humidified atmosphere of 5% CO 2 . To induce macrophage differentiation, THP-1 monocytes were seeded at a density of 5Â10 5 cells per ml in a six-well plate or a 10-cm dish and treated with 200 nM phorbol 12-myristate 13-acetate (PMA) (Calbiochem, San Diego, CA, USA) for 48 h. After the incubation, nonadherent cells and PMA were aspirated and the adherent cells, which resembled mature macrophages, were washed twice with RPMI-1640 medium without FCS and P/S. THP-1 macrophages were then incubated in RPMI-1640 medium without FCS and P/S overnight using a serum starvation condition. AngII (Sigma), LPS (Salmonella, Sigma), losartan (LKT Laboratories, St Paul, MN, USA), GW9662 (Sigma) and T0070907 (Sigma) were diluted with phosphate-buffered saline (Gibco) or dimethylsulphoxide (Sigma) and applied to the THP-1 macrophages at the concentrations indicated in the text and figures.
Analysis of mRNA expression
Total RNA was extracted from the treated or untreated THP-1 macrophages using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. Complementary DNA (cDNA) was synthesized by reverse transcription (RT) from 1 mg of RNA using the PrimeScript RT reagent kit (Takara, Tokyo, Japan) according to the manufacturer's protocol. The cDNA was used as the template in a RT-PCR to analyze the gene expression of angiotensinogen, renin, angiotensin-converting enzyme (ACE), IL-8, TNF-a and COX-2. Quantitative RT-PCR analysis was carried out using SYBR Premix Ex Taq (Takara). Relative quantification was carried out using the comparative Ct method, and glyceraldehyde-3-phosphate dehydrogenase served as the control. The sequences of the oligonucleotide primers used in the RT-PCR analyses are available on request.
Immunoblotting analysis
Cultured cells in the 10-cm dish were washed twice with phosphate-buffered saline and lysed using prechilled lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA and 1% Triton) containing a protease inhibitor cocktail (Sigma). When the phosphorylation status was examined, 5 mM NaF and 2 mM Na 3 VO 4 were added to prevent protein dephosphorylation. After measuring the protein concentration using the bicinchoninic acid (BCA) protein assay reagent (Pierce Biotechnology, Rockford, IL, USA), equal concentrations of protein diluted in 2Â Laemmli buffer (50 mM Tris-HCl, 150 mM NaCl, 10% Gly, 4% SDS) were separated by SDS polyacrylamide gel electrophoresis and then transferred to a nitrocellulose membrane (Invitrogen). Nonspecific binding was blocked by preincubating the membrane in 5% skim milk (BD, Sparks, MD, USA) in a TBS 0.1% Tween 20 (Wako, Osaka, Japan) solution. Subsequently, the membrane was incubated with primary antibodies against AT1R (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), glyceraldehyde-3-phosphate dehydrogenase (1:200) (Santa Cruz Biotechnology), phospho-IkB (1:1000) (Cell Signaling Technology, Danvers, MA, USA) or total-IkB (1:1000) (Cell Signaling Technology), and were then incubated with secondary rabbit anti-mouse or goat anti-rabbit IgG horseradish peroxidase-conjugated antibodies (1:1000) (Dako, Tokyo, Japan). Signals on the membrane were visualized by chemiluminescence (Image Reader LAS-3000; Fujifilm, Tokyo, Japan), and their densities were quantified using MultiGauge Ver. 3.1 (Fujifilm, Tokyo, Japan).
Statistical analysis
Bar graph data are expressed as means±s.d. Statistical comparisons were carried out using one-way analysis of variance followed by a post hoc Tukey's or Dunnett's multiple comparison tests. The results were considered statistically significant if the P value was o0.05.
RESULTS
Losartan inhibits LPS-induced expression of proinflammatory genes
The effect of the AT1R antagonist losartan on the LPS-induced expression of proinflammatory genes in the THP-1 cell line was evaluated by a quantitative RT-PCR method. THP-1 cells were treated with PMA to differentiate from a monocyte-like phenotype to a macrophage-like phenotype, and after 3 h of treatment with LPS, the steady-state mRNA levels of TNF-a, IL-8 and COX-2 were investigated in THP-1 macrophages. As shown in Figures 1a-c with losartan attenuated the LPS-induced expression of these proinflammatory genes. The decreased expression levels of TNF-a, IL-8 and COX-2 were related to the concentration of losartan in a dosedependent manner (Figures 1d-f, respectively) .
Expression of RAS component genes
We evaluated the expression of RAS components such as angiotensinogen, renin, ACE and AT1R in THP-1 macrophages. The expression of AT1R was detected at the protein level (Figure 2a) . On the other hand, except for angiotensinogen, the expression of RAS components essential for the production of AngII could not be detected at the mRNA level (Figure 2b ). In addition, LPS did not change the expression of the RAS components (Figure 2 ). These data suggest that the AngII autocrine pathway did not exist in THP-1 macrophages.
Effects of AngII on expression levels of proinflammatory genes
The inhibitory effects of losartan on LPS-induced inflammatory responses prompted us to investigate whether AngII-AT1R activation would enhance LPS-induced signaling. The effect of AngII on the expression of proinflammatory genes was analyzed using quantitative RT-PCR 12 h after treatment with AngII in the presence or absence of LPS. As demonstrated in Figure 3 , AngII showed no additive effects on LPS-induced proinflammatory gene expression. In addition, AngII alone had no effect on proinflammatory gene expression. These observations suggest that AngII-AT1R activation does not affect LPS-induced inflammatory responses.
Effects of losartan on LPS-induced phosphorylation of IjB
It is widely accepted that the IkK-IkB-NFkB activation pathway has a central role in proinflammatory gene expression downstream of the LPS-TLR4 pathway. 8 To further dissect the mechanism of losartanmediated inhibition of LPS-induced inflammatory signals, we asked whether losartan would inhibit a downstream signal of the LPS-TLR4 pathway, that is, IkB phosphorylation. As indicated in Figure 4 , LPS induced the phosphorylation of IkB, and losartan did not attenuate this phosphorylation.
Effects of losartan and PPARc antagonists on LPS-induced proinflammatory gene expression As AT1R blockers have recently been implicated as functional agonists of PPARg, 12 we investigated whether losartan would exert anti-inflammatory effects as a PPARg agonist in our experimental macrophage system. We used two different PPARg antagonists, GW9662 and T0070907, in studying the effects on LPS-induced proinflammatory gene expression. Treatment with GW9662 or T0070907 significantly counteracted the inhibitory effects of losartan on TNF-a and IL-8 expression, whereas GW9662 or T0070907 alone had no effect on LPS-induced proinflammatory gene expression (Figures 5a, b, d and e). In addition, cotreatment of losartan with GW9662 or T0070907 did not affect the LPS-induced IkB phosphorylation level (Figure 4 ). On the other hand, the effect of these PPARg antagonists against losartan was not observed for COX-2 expression (Figures 5c and f) . These findings suggest that losartan attenuates LPS-induced proinflammatory gene expression at least in part by acting as a PPARg agonist.
DISCUSSION
We detected no interaction between RAS and the LPS-TLR4 inflammatory signaling pathway in human THP-1 macrophages in this study. Although losartan induced anti-inflammatory effects, it did so independent of its antagonistic role against AT1R, because AngII showed no effect on proinflammatory gene expression. Surprisingly, AngII itself had little effect on inflammatory gene expression despite the expression of AT1R in THP-1 macrophages. It has been reported that AngII induced inflammatory gene expression in endothelial cells, vascular smooth muscle cells and blood vessel tissues. 4 The reason why AngII does not induce proinflammatory gene expression in THP-1 macrophages remains unknown, but the concentration of AngII used is not likely to be a factor because we tested a wide range of dose-dependent effects. Nevertheless, our results show that THP-1 macrophages lack the essential components to produce AngII, suggesting that AngII was not produced by the macrophages themselves and that the RAS was not involved in the inhibitory effect of losartan in THP-1 macrophages. These findings are in good agreement with those of the recent reports showing that another AT1R blocker, candesartan, reduced the LPS-induced innate immune response by a mechanism that is unrelated to AT1R inhibition. 13, 14 In this study, we used a high concentration (100 mM) of losartan, which was far from a physiological concentration in vivo, calling into question the significance of our findings. However, we demonstrated the dose-dependent effects of losartan on LPS-induced inflammatory gene expression in THP-1 macrophages (Figures 1d-f) . These observations suggest that losartan could suppress the inflammatory signals at even lower concentrations, although the effects would be small at physiological concentrations in vivo.
We investigated the effect of losartan on LPS-induced phosphorylation of IkB in THP-1 macrophages. The IkK-IkB-NFkB complex has an essential role in proinflammatory gene expression, and the TLR signaling is the main inducer of IkK-IkB-NFkB activation. IkK phosphorylates IkB, leading to degradation, which allows free NFkB to translocate into the nucleus and regulates the transcription of target genes, including inflammatory cytokines and chemokines. 8 We speculated that the inhibitory effects of losartan on LPS-induced proinflammatory gene expression were mediated by IkK-IkB-NFkB signaling because studies showed that AT1R blockers exerted antiinflammatory effects by suppressing IkK-IkB-NFkB activation. 15, 16 However, our data show that losartan has no effect on LPS-induced IkB phosphorylation, suggesting that losartan does not inhibit LPSinduced signaling through the IkK-IkB-NFkB pathway, at least at the level of NF-kB activation.
Recently, functions for AT1R blockers other than antagonizing AT1R have been reported. For instance, EXP3179, an active metabolite of losartan synthesized by the cytochrome P450 pathway, shows structural homology with indomethacin, a COX inhibitor, which inhibits the COX-2-dependent activation of thromboxane A2 and prostaglandin F2a. 17 EXP3179 has also been reported to have a distinct activity as a PPARg agonist. 12, 18 In addition, another AT1R blocker, telmisartan, has structural similarity to PPARg agonists and is reported to affect glucose and lipid metabolism in the same manner as PPARg agonists. 19 It has been reported that the activated PPARg-signaling pathway inhibits proinflammatory gene expression in macrophages. 20, 21 In this study, we investigated the effects of two different PPARg antagonists, GW9662 and T0070907, on LPS-induced proinflammatory gene expression. Although GW9662 and T0070907 themselves had no effect, these antagonists counteracted the inhibitory effects of losartan on TNF-a and IL-8 expression. Although it was not evident whether a cytochrome P450 pathway could synthesize the metabolite EXP3179 in THP-1 macrophages, the expression of cytochrome P450 isoenzymes, 2C9 and 3A4, which are linked to losartan metabolism, is well defined in the lineage of monocytes/macrophages. 22, 23 Alternatively, it was reported that losartan itself could serve as a PPARg agonist, 12 supporting the idea that losartan attenuates LPS-induced proinflammatory gene expression by acting as a PPARg agonist. In this study, we did not use other AT1R blockers with strong PPARg activity, such as telmisartan and irbesartan, or PPARg agonists, such as glitazone, to demonstrate the involvement of the PPARg pathway because we wanted to clarify the interaction between RAS and TLR-signaling pathways in macrophages. In addition, the direct use of PPARg agonists might be problematic because of their antiinflammatory effects, which can act, at least in part, through PPARgindependent mechanisms. 24 Instead, we evaluated two different PPARg antagonists on losartan-induced anti-inflammatory gene expression to demonstrate the PPARg agonistic effects of losartan. Importantly, the effects of GW9662 and T0070907 against losartan were independent of the IkK-IkB-NFkB activation pathway. These results were consistent with the reports that PPARg agonists repress the expression of inflammatory genes through NF-kB/IRF-independent mechanisms. In addition, PPARg was reported to affect the mRNA stability of inflammatory genes without interfering with the NF-kB complex. 25, 26 However, it should be noted here that COX-2 expression was still reduced after being treated with GW9662 or T0070907. In fact, losartan or its metabolite EXP3179 could also function as a thromboxane A2 receptor blocker and COX inhibitor, 27 implying that other regulatory mechanisms might be involved in the losartan-mediated suppression of LPS-induced inflammatory signaling.
In conclusion, RAS did not have a crucial role in LPS-induced proinflammatory gene expression in the human THP-1 macrophage system. We demonstrated that losartan inhibits LPS-induced proinflammatory gene expression through a PPARg-dependent pathway, and this effect is independent of its antagonistic action against AT1R.
